These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29123959)

  • 21. Identification of glypican-3-derived long peptides activating both CD8
    Sayem MA; Tomita Y; Yuno A; Hirayama M; Irie A; Tsukamoto H; Senju S; Yuba E; Yoshikawa T; Kono K; Nakatsura T; Nishimura Y
    Oncoimmunology; 2016; 5(1):e1062209. PubMed ID: 26942076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
    Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
    Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
    Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
    Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-Generation Cancer Immunotherapy Targeting Glypican-3.
    Shimizu Y; Suzuki T; Yoshikawa T; Endo I; Nakatsura T
    Front Oncol; 2019; 9():248. PubMed ID: 31024850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector.
    Liu Q; Yang Y; Tan X; Tao Z; Adah D; Yu S; Lu J; Zhao S; Qin L; Qin L; Chen X
    Oncotarget; 2017 Apr; 8(15):24785-24796. PubMed ID: 28445973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
    Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
    Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8
    Zheng Y; Lu Z; Ding J; Jiang N; Wang J; Yang J; Song J; Chen H; Fang L; Li H; Tian H; Wang G; Zheng J; Chai D
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
    Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
    Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination.
    Takeda K; Kitaura K; Suzuki R; Owada Y; Muto S; Okabe N; Hasegawa T; Osugi J; Hoshino M; Tsunoda T; Okumura K; Suzuki H
    Cancer Immunol Immunother; 2018 Jun; 67(6):949-964. PubMed ID: 29568993
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
    Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
    Haruyama Y; Kataoka H
    World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
    Daiko H; Marafioti T; Fujiwara T; Shirakawa Y; Nakatsura T; Kato K; Puccio I; Hikichi T; Yoshimura S; Nakagawa T; Furukawa M; Stoeber K; Nagira M; Ide N; Kojima T
    Cancer Immunol Immunother; 2020 Nov; 69(11):2247-2257. PubMed ID: 32500232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
    Filmus J; Capurro M
    FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis.
    Hayashi E; Motomura Y; Shirakawa H; Yoshikawa T; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2009 Jul; 22(1):149-54. PubMed ID: 19513517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
    Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
    Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model.
    Fujinami N; Yoshikawa T; Sawada Y; Shimomura M; Iwama T; Sugai S; Kitano S; Uemura Y; Nakatsura T
    Biochem Biophys Rep; 2016 Mar; 5():482-491. PubMed ID: 28955856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.